Analyst Price Targets — NEXI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 16, 2022 8:04 am | — | Barclays | $2.00 | $1.19 | Benzinga | Barclays Maintains Overweight on NexImmune, Lowers Price Target to $2 |
| August 16, 2022 7:28 am | — | Raymond James | $3.00 | $1.26 | Benzinga | Raymond James Maintains Outperform on NexImmune, Lowers Price Target to $3 |
| June 1, 2022 7:28 am | — | BTIG | $5.00 | $2.28 | Benzinga | BTIG Initiates Coverage On NexImmune with Buy Rating, Announces Price Target of $5 |
Latest News for NEXI
Risk and Volatility NexImmune has a beta of -2289.14, suggesting that its share price is 229,014% less volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Profitability This table compares NexImmune and Graybug Vision's net margins, return on
NexImmune, Inc. (NASDAQ: NEXI - Get Free Report)'s share price shot up 2,169,900% during mid-day trading on Tuesday. The stock traded as high as $2.17 and last traded at $2.17. 12,837 shares changed hands during trading, an increase of 176% from the average session volume of 4,645 shares. The stock had previously closed at $0.0001.
Profitability This table compares NexImmune and Avenue Therapeutics' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets NexImmune N/A -534.32% -213.72% Avenue Therapeutics N/A -471.57% -296.50% Volatility and Risk NexImmune has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NEXI.
U.S. House Trading
No House trades found for NEXI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.